{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:22:22Z","timestamp":1779920542785,"version":"3.53.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canlet.2024.217318","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:46:16Z","timestamp":1731084376000},"page":"217318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Precision meets repurposing: Innovative approaches in human papillomavirus and Epstein-Barr virus-driven cancer therapy"],"prefix":"10.1016","volume":"607","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3253-3529","authenticated-orcid":false,"given":"Queenie","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib1","article-title":"Origins of cancer therapy","volume":"74","author":"Papac","year":"2001","journal-title":"Yale J. Biol. Med."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: a critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2024.217318_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.canlet.2024.217318_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(01)00587-3","article-title":"Metronomic scheduling: the future of chemotherapy?","volume":"2","author":"Gasparini","year":"2001","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.canlet.2024.217318_bib6","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib7","article-title":"Antiangiogenic scheduling of lower dose cancer chemotherapy","volume":"7","author":"Gately","year":"2001","journal-title":"Cancer Journal"},{"issue":"11","key":"10.1016\/j.canlet.2024.217318_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-04-0580","article-title":"A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens","volume":"64","author":"Emmenegger","year":"2004","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2024.217318_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2024.217318_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2015.131","article-title":"Clinical overview of metronomic chemotherapy in breast cancer","volume":"12","author":"Munzone","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib11","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J. Obstet. Gynaecol. (Lahore)."},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib13","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-19-0038","article-title":"Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States","volume":"28","author":"Mahal","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12030424","article-title":"Coinfection of HPVs is associated with advanced stage in colorectal cancer patients from Qatar","volume":"12","author":"Fernandes","year":"2023","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.canlet.2024.217318_bib15","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1111\/codi.12257","article-title":"Human papillomavirus infection and colorectal cancer risk: a meta-analysis","volume":"15","author":"Damin","year":"2013","journal-title":"Color. Dis."},{"key":"10.1016\/j.canlet.2024.217318_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad205","article-title":"Human papillomavirus-associated anal cancer incidence and burden among US men, according to sexual orientation, human immunodeficiency virus (HIV) status, and age","author":"Deshmukh","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.canlet.2024.217318_bib17","article-title":"Human papillomaviruses-related cancers: an update on the presence and prevention strategies in the Middle East and north african regions","volume":"11","author":"Fernandes","year":"2022","journal-title":"Pathog. (Basel, Switzerland)"},{"issue":"JUL","key":"10.1016\/j.canlet.2024.217318_bib18","article-title":"Role of Epstein-Barr virus in the pathogenesis of head and neck cancers and its potential as an immunotherapeutic target","volume":"8","author":"Fernandes","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217318_bib19","article-title":"The role of EBV in the pathogenesis of diffuse large B cell lymphoma","volume":"390","author":"Healy","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein\u2013Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib21","article-title":"Co-presence of Epstein\u2013Barr virus and high-risk human papillomaviruses in Syrian colorectal cancer samples","volume":"16","author":"Malki","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9040300","article-title":"Human papillomaviruses and epstein\u2013barr virus interactions in colorectal cancer: a brief review","volume":"9","author":"Fernandes","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.canlet.2024.217318_bib23","article-title":"Incidence and association of high-risk HPVs and EBV in patients with advanced stages of colorectal cancer from Qatar","author":"Queenie","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2024.217318_bib24","series-title":"Advances in Health and Disease","first-page":"1","article-title":"Chapter 1. Vaccines and immunotherapies against the human papillomavirus and Epstein-Barr virus","author":"Queenie Fernandes","year":"2022"},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human viral oncogenesis: a cancer hallmarks analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"180","key":"10.1016\/j.canlet.2024.217318_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24976\/Discov.Med.202436180.1","article-title":"Beyond viral infections: the multifaceted roles of human papillomavirus and Epstein-Barr virus in shaping the tumor microenvironment","volume":"36","author":"Fernandes","year":"2024","journal-title":"Discov. Med."},{"issue":"9","key":"10.1016\/j.canlet.2024.217318_bib27","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","article-title":"Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial","volume":"30","author":"Mo","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9","article-title":"Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma","volume":"92","author":"Lindel","year":"2001","journal-title":"Cancer"},{"issue":"27","key":"10.1016\/j.canlet.2024.217318_bib29","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217318_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/1751-2980.12236","article-title":"The impact of human papillomavirus infection on the survival and treatment response of patients with esophageal cancers","volume":"16","author":"Wang","year":"2015","journal-title":"J. Dig. Dis."},{"issue":"12","key":"10.1016\/j.canlet.2024.217318_bib32","article-title":"Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis","volume":"48","author":"O'Rorke","year":"2012","journal-title":"Oral Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2024.217318_bib33","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0037","article-title":"Clinical behavior and treatment response of Epstein-Barr virus-positive metastatic gastric cancer: implications for the development of future trials","volume":"25","author":"Corallo","year":"2020","journal-title":"Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib34","article-title":"Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis","volume":"63","author":"Constanza Camargo","year":"2014","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.canlet.2024.217318_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70017-6","article-title":"HPV-associated head and neck cancer: a virus-related cancer epidemic","volume":"11","author":"Marur","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.217318_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2017.03.006","article-title":"Quality of life in survivors of oropharyngeal cancer: a systematic review and meta-analysis of 1366 patients","volume":"78","author":"H\u00f8xbroe Michaelsen","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8100095","article-title":"Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites","volume":"8","author":"Tomai\u0107","year":"2016","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine","volume":"14","author":"Welters","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2024.217318_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with human papillomavirus type 16 (HPV-16)-Associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2013.08.025","article-title":"Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape","volume":"131","author":"Conesa-Zamora","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-012-1322-5","article-title":"Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine","volume":"62","author":"Peng","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.12515","article-title":"Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer","volume":"43","author":"Tsai","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"issue":"7785","key":"10.1016\/j.canlet.2024.217318_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(72)92402-6","article-title":"Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis","volume":"300","author":"Gerber","year":"1972","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.canlet.2024.217318_bib47","article-title":"Epstein-Barr virus (EBV) and human disease: facts, opinions and problems","volume":"462","author":"Griffin","year":"2000","journal-title":"Mutat. Res. - Rev. Mutat. Res."},{"key":"10.1016\/j.canlet.2024.217318_bib48","article-title":"Proceedings of the IARC working group on the evaluation of carcinogenic risks to humans. Epstein-barr virus and Kaposi's Sarcoma Herpesvirus\/human Herpesvirus 8. Lyon, France, 17-24 June 1997","volume":"vol. 70","year":"1997"},{"key":"10.1016\/j.canlet.2024.217318_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2014.01.003","article-title":"Epigenetic regulation of EBV persistence and oncogenesis","volume":"26","author":"Tempera","year":"2014","journal-title":"Semin. Cancer Biol."},{"issue":"SUPPL. 32","key":"10.1016\/j.canlet.2024.217318_bib50","article-title":"Potential role of Epstein-Barr virus in Sjogren's syndrome and rheumatoid arthritis","volume":"19","author":"Fox","year":"1992","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.27","article-title":"Epstein-barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-017-9693-x","article-title":"Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma","volume":"36","author":"Nakanishi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2024.217318_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2014.01.004","article-title":"Individualized treatment in stage IVC nasopharyngeal carcinoma","volume":"50","author":"Chan","year":"2014","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-019-03858-7","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study","volume":"84","author":"Kong","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217318_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103244","article-title":"Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: an updated network meta-analysis","volume":"160","author":"Bongiovanni","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-022-02158-4","article-title":"The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study","volume":"17","author":"Wang","year":"2022","journal-title":"Radiat. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2024.217318_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps6100","article-title":"Multicenter, randomized, controlled, open-label study of bevacizumab combined with carboplatin and paclitaxel versus carboplatin and paclitaxel in patients with metastatic nasopharyngeal carcinoma","volume":"32","author":"Zhang","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2004.07.702","article-title":"Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience","volume":"61","author":"Lee","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2015.01.008","article-title":"Metronomic chemotherapy from rationale to clinical studies: a dream or reality?","volume":"95","author":"Gnoni","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.217318_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.canlet.2024.217318_bib63","volume":"327","year":"2022","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"9980","key":"10.1016\/j.canlet.2024.217318_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.canlet.2024.217318_bib65","article-title":"Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma","volume":"96","author":"Lee","year":"2017","journal-title":"Med. (United States)"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2014.01.052","article-title":"Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid","volume":"89","author":"Twu","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib67","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000002547","article-title":"Metronomic chemotherapy for Burkitt lymphoma in a patient with HIV: case report","volume":"45","author":"Dwivedi","year":"2023","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.canlet.2024.217318_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237162","article-title":"Remarkable Remission rate and long-term efficacy of Upfront metronomic chemotherapy in Elderly and Frail patients, with diffuse large B-cell lymphoma","volume":"11","author":"Bocci","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2024.217318_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216900","article-title":"Metronomic chemotherapy in hematology: lessons from preclinical and clinical studies to build a solid rationale for future schedules","volume":"591","author":"Banchi","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2011.10.028","article-title":"Transcriptional gene silencing of HPV16 E6\/E7 induces growth inhibition via apoptosis in vitro and in vivo","volume":"124","author":"Zhou","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217318_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.26197","article-title":"The synergistic therapeutic effect of cisplatin with Human papillomavirus E6\/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo","volume":"130","author":"Jung","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2008.06.033","article-title":"Gene silencing with siRNA targeting E6\/E7 as a therapeutic intervention in a mouse model of cervical cancer","volume":"111","author":"Jonson","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib73","article-title":"Repositioning fenofibrate to reactivate p53 and reprogram the tumor-immune microenvironment in HPV+ head and neck squamous cell carcinoma","volume":"14","author":"Quinn O'Neill","year":"2022","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.canlet.2024.217318_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168693","article-title":"Bazedoxifene, a gp130 inhibitor, modulates emt signaling and exhibits antitumor effects in hpv-positive cervical cancer","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib75","article-title":"Update on bazedoxifene: a novel selective estrogen receptor modulator","volume":"2","author":"Biskobing","year":"2007","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.canlet.2024.217318_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122390","article-title":"Chronic inflammation and cancer; the two sides of a coin","volume":"338","author":"Fernandes","year":"2024","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib77","article-title":"Blocking interleukin-6 signaling inhibits cell viability\/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells","volume":"52","author":"Chen","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2024.217318_bib78","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-15-0921","article-title":"Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy","volume":"15","author":"Wu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2024.217318_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2019.01.026","article-title":"Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer","volume":"448","author":"Fu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217318_bib80","series-title":"Medicinal Plants of China","author":"Duke","year":"1985"},{"key":"10.1016\/j.canlet.2024.217318_bib81","volume":"vol. 2","author":"Satyavati","year":"1987"},{"key":"10.1016\/j.canlet.2024.217318_bib82","series-title":"Encyclopedia of Herbs & Their uses\/Bown D","first-page":"283","author":"Bown","year":"1995"},{"key":"10.1016\/j.canlet.2024.217318_bib83","series-title":"The Encyclopedia of Medicinal plants. New York: DK Pub","author":"Chevalier","year":"1996"},{"key":"10.1016\/j.canlet.2024.217318_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.757414","article-title":"Targeting Aberrant expression of STAT3 and AP-1 oncogenic transcription factors and HPV oncoproteins in cervical cancer by Berberis aquifolium","volume":"12","author":"Singh","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217318_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/29.3.245","article-title":"Tetracyclines, molecular and clinical aspects","volume":"29","author":"Chopra","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib86","doi-asserted-by":"crossref","DOI":"10.1139\/cjpp-2015-0481","article-title":"Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and negative cervical cancer cell lines","volume":"94","author":"Zhao","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.febslet.2013.01.042","article-title":"HPV E6 induces eIF4E transcription to promote the proliferation and migration of cervical cancer","volume":"587","author":"Wang","year":"2013","journal-title":"FEBS Lett."},{"issue":"14","key":"10.1016\/j.canlet.2024.217318_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02380-05","article-title":"Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein","volume":"80","author":"Oh","year":"2006","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib89","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2010.496506","article-title":"Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?","volume":"51","author":"Borden","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharep.2016.05.007","article-title":"Repositioning of anti-viral drugs as therapy for cervical cancer","volume":"68","author":"Sharma","year":"2016","journal-title":"Pharmacol. Reports"},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(00)70217-4","article-title":"Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C","volume":"118","author":"Cramp","year":"2000","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00010-06","article-title":"Viral determinants of resistance to treatment in patients with hepatitis C","volume":"20","author":"Wohnsland","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib93","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.2205005","article-title":"Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation","volume":"168","author":"Chiang","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/135965350601100607","article-title":"Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro","volume":"11","author":"Hampson","year":"2006","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib95","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3851\/IMP1786","article-title":"Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells","volume":"16","author":"Batman","year":"2011","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2011.05.016","article-title":"Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions","volume":"91","author":"Zehbe","year":"2011","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217318_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0b013e328351f7a5","article-title":"Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity","volume":"26","author":"Barillari","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.canlet.2024.217318_bib98","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-virology-110615-042358","article-title":"Epstein-Barr virus: the path from latent to productive infection","volume":"3","author":"Chiu","year":"2016","journal-title":"Annual Review of Virology"},{"issue":"46","key":"10.1016\/j.canlet.2024.217318_bib99","article-title":"Epstein-Barr virus replicating in epithelial cells","volume":"111","author":"Hutt-Fletcher","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/JVI.01512-10","article-title":"A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.canlet.2024.217318_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.22.13993-14003.2005","article-title":"Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040120","article-title":"Perspective: contribution of Epstein-Barr virus (EBV) reactivation to the carcinogenicity of nasopharyngeal cancer cells","volume":"10","author":"Wu","year":"2018","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050997","article-title":"Novel therapeutics for epstein\u2013barr virus","volume":"24","author":"Andrei","year":"2019","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers"},{"issue":"4\u20136","key":"10.1016\/j.canlet.2024.217318_bib105","article-title":"Dipyridamole, cerebrovascular disease, and the vasculature","volume":"48","author":"Chakrabarti","year":"2008","journal-title":"Vascul. Pharmacol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217318_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.45.12.3657-3659.2001","article-title":"Inhibition of herpes simplex virus reactivation by dipyridamole","volume":"45","author":"Tenser","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.canlet.2024.217318_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.17.11062-11070.2005","article-title":"Dipyridamole reversibly inhibits Mengovirus RNA replication","volume":"79","author":"Fata-Hartley","year":"2005","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.35.6.1250","article-title":"Differential inhibition of 2\u2019-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2\u2019,3\u2019-dideoxycytidine by dipyridamole","volume":"35","author":"Patel","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.canlet.2024.217318_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104615","article-title":"Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation","volume":"172","author":"Thom\u00e9","year":"2019","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-61300-y","article-title":"Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines","volume":"10","author":"Kotaki","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-014-0628-7","article-title":"Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections","volume":"14","author":"Naber","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"12","key":"10.1016\/j.canlet.2024.217318_bib112","first-page":"476","article-title":"Clinical pharmacokinetics of nitroxoline","volume":"17","author":"Mrhar","year":"1979","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib113","doi-asserted-by":"crossref","DOI":"10.1097\/CAD.0000000000000466","article-title":"Nitroxoline shows antimyeloma activity by targeting the TRIM25\/p53 axle","volume":"28","author":"Mao","year":"2017","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42088-y","article-title":"Assessment of early therapeutic response to nitroxoline in Temozolomide-resistant Glioblastoma by amide proton transfer imaging: a preliminary comparative study with diffusion-weighted imaging","volume":"9","author":"Kumari","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib115","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2016.4380","article-title":"Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing","volume":"11","author":"Zhang","year":"2016","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib116","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41429-021-00433-2","article-title":"Rationally repurposed nitroxoline inhibits preclinical models of Epstein\u2013Barr virus-associated lymphoproliferation","volume":"74","author":"Ib\u00e1\u00f1ez de Garayo","year":"2021","journal-title":"J. Antibiot. (Tokyo)."},{"issue":"22","key":"10.1016\/j.canlet.2024.217318_bib117","doi-asserted-by":"crossref","DOI":"10.7150\/jca.47025","article-title":"Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity","volume":"11","author":"Xu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2024.217318_bib118","article-title":"Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells","volume":"9","author":"Chan-On","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.canlet.2024.217318_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2011.12.031","article-title":"Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model","volume":"148","author":"Zhang","year":"2012","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.canlet.2024.217318_bib120","doi-asserted-by":"crossref","DOI":"10.1093\/emboj\/20.11.2641","article-title":"CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex","volume":"20","author":"Kaykas","year":"2001","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.canlet.2024.217318_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047703","article-title":"Repositioning antimicrobial agent pentamidine as a disruptor of the lateral interactions of transmembrane domain 5 of EBV latent membrane protein 1","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib122","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00831-5","article-title":"Dose-reduction trials in oncology \u2014 aiming for less toxicity and better quality of life at lower costs","volume":"21","author":"Theilgaard-M\u00f6nch","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217318_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib125","article-title":"Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?","volume":"2019","author":"Renner","year":"2019","journal-title":"J. Glob. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217318_bib126","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2024.217318_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.40","article-title":"Determining the optimal dose in the development of anticancer agents","volume":"11","author":"Mathijssen","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2024.217318_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70056-1","article-title":"Has the time come for metronomics in low-income and middle-income countries?","volume":"14","author":"Andr\u00e9","year":"2013","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217318_bib129","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-013-9974-3","article-title":"Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy","volume":"32","author":"Chow","year":"2014","journal-title":"Invest. New Drugs"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2024.217358","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:35:41Z","timestamp":1760816141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":129,"alternative-id":["S0304383524007134"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217318","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.canlet.2024.217358","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision meets repurposing: Innovative approaches in human papillomavirus and Epstein-Barr virus-driven cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217318"}}